Today: 21 May 2026
Oil prices today: Brent, WTI dip as Strait of Hormuz warning keeps Iran risk premium in play
10 February 2026
2 mins read

Oil prices today: Brent, WTI dip as Strait of Hormuz warning keeps Iran risk premium in play

London, Feb 10, 2026, 11:20 GMT — Regular session

  • Brent lost 24 cents, landing at $68.80 a barrel. WTI eased down 30 cents to $64.06.
  • U.S.-Iran tensions and fresh shipping guidance for the Strait of Hormuz kept traders’ attention locked in.
  • Traders are eyeing U.S. oil inventory numbers set for release Wednesday, with the data seen as the next catalyst.

Oil eased back on Tuesday, giving up some of Monday’s gains as traders kept a close eye on potential supply shocks stemming from escalating U.S.-Iran friction. Brent crude slipped 24 cents to $68.80 a barrel by 1002 GMT, a 0.35% drop. U.S. West Texas Intermediate lost 30 cents, or 0.47%, to $64.06. “Unless there are concrete signs of supply disruptions, prices will likely start going lower,” said Tamas Varga, oil analyst at PVM. Reuters

Washington’s newest advisory to ships in the region set things off. The U.S. Department of Transportation’s Maritime Administration told U.S.-flagged commercial vessels to keep their distance from Iran’s territorial waters when crossing the Strait of Hormuz, and, per the guidance posted online, to refuse if Iranian forces attempt to board.

Headlines like that keep a risk premium—buyers shelling out extra for a shot at disruption—baked into crude prices, even if supply isn’t short. Reuters reported Monday that the CBOE crude oil volatility index just hit its highest mark since last June. The International Energy Agency, meanwhile, still sees output topping demand by 3.7 million barrels per day this year. The oil forward curve? Deep backwardation, with front-month contracts trading well above later ones—typically a sign of a market worried about near-term supply.

Supply signals went both ways. OPEC’s oil production edged lower in January, according to a Reuters survey, as the group logged 28.34 million barrels per day—60,000 barrels per day below December’s level. OPEC+ also halted its usual monthly output hikes for the first quarter, citing worries over a possible glut.

The EU is weighing fresh sanctions on Russia, with a proposal to target ports in Georgia and Indonesia that process Russian oil, according to a document seen by Reuters. For the move to take effect, all EU member states would have to sign off.

Trade routes in Asia are getting a shakeup as politics and pricing take the front seat. Indian Oil Corp and Hindustan Petroleum, both state-run, have snapped up 2 million barrels of Venezuela’s Merey crude—scheduled to land in the back half of April, according to two traders who spoke with Reuters. Trafigura is handling the sale.

The market faces a straightforward dilemma: investors are pricing in potential scenarios, not current realities. Should shipments through Hormuz continue undisturbed and diplomatic tensions ease, that geopolitical premium could deflate quickly, pushing crude back into a pattern where supply narratives outweigh geography.

Traders are now looking to U.S. inventories for direction. The Energy Information Administration will drop its Weekly Petroleum Status Report this Wednesday, Feb. 11, hitting at 10:30 a.m. Eastern as usual.

Macro drivers aren’t far from focus. The U.S. Labor Department plans to publish January’s consumer price index on Friday, Feb. 13 at 8:30 a.m. Eastern—a key print with the potential to jolt the dollar, and with it, dollar-denominated commodities.

The International Energy Agency is set to release its February Oil Market Report this Thursday, Feb. 12, giving the market an updated snapshot on demand and supply assumptions. Right now, focus hasn’t shifted: traders are tracking Gulf headlines and checking if the data justifies that risk premium.

Stock Market Today

  • Sudarshan Colorants India's Earnings Show Potential Despite Profit Dip
    May 20, 2026, 8:53 PM EDT. Sudarshan Colorants India Limited (NSE:SUDARCOLOR) reported weaker profits last quarter, impacted by ₹50 million in unusual expenses that are unlikely to recur, suggesting potential profit rebound. The company's earnings per share (EPS) are growing strongly, indicating solid underlying business performance. Investors should consider balance sheet strength and monitor two identified warning signals, one considered significant. While profit was soft this time, analysts view Sudarshan Colorants' earnings outlook as cautiously optimistic, citing quality income statement elements and possible earnings improvements in the next quarter.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution
Previous Story

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution

Snap stock jumps in premarket after analyst upgrade as SNAP tries to rebound
Next Story

Snap stock jumps in premarket after analyst upgrade as SNAP tries to rebound

Go toTop